Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Maintains Growth Trajectory For Vytorin, Zetia – For Now

This article was originally published in The Pink Sheet Daily

Executive Summary

Company gets subpoenas from New York State Attorney General, acknowledges as many as 50 civil class action suits over ENHANCE trial.

You may also be interested in...



Merck Gets Janumet Label Extended

Combo drug’s new indications follow similar extensions last year for the pair when taken in tandem.

Merck Gets Janumet Label Extended

Combo drug’s new indications follow similar extensions last year for the pair when taken in tandem.

Schering-Plough Hopes To Enhance Confidence In Vytorin/Zetia With Monthly Rx Data

Firm feeling impact on sales from Vytorin study results.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel